TL;DR
This study investigates the interaction mechanisms between DEK protein and its aptamer (DTA) to improve DTA's stability for treating inflammatory arthritis. By computationally modifying DTA with methoxy groups (DTA_OMe) and performing molecular dynamics simulations, they found that the modification enhances stability without significantly compromising affinity, suggesting a promising strategy for aptamer design.
What Problem Does This Paper Address?
Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are debilitating autoimmune diseases. The DEK protein plays a role in neutrophil extracellular trap (NET) formation, which contributes to the pathogenesis of these inflammatory conditions. DEK-targeted aptamers (DTAs) have shown potential in reducing NET formation and thus treating inflammatory arthritis. However, a major hurdle for DTA's clinical application is its poor stability in vivo, primarily due to degradation by nucleases. This paper aims to address this limitation by exploring modifications to enhance DTA's stability while maintaining its therapeutic efficacy.
Methods
The researchers employed a multi-faceted computational approach:
- Structural Preparation: They obtained the structures of the DEK protein's N-terminal (DEK_N) and C-terminal (DEK_C) domains from the Protein Data Bank. The DTA aptamer's 3D structure was predicted using a pipeline involving RNAstructure, RNAComposer, and ModeRNA.
- Force Field Development: A crucial step was establishing a specialized force field for the 2'-OCH<sub>3</sub>-modified nucleotides (DTA_OMe) to accurately model their behavior in simulations. This involved optimizing parameters for six non-standard nucleotide fragments.
- Protein-DNA Docking: They used the HDOCK server to predict the binding poses of DTA and DTA_OMe with both DEK_N and DEK_C domains, generating four protein-DNA complex models.
- Molecular Dynamics (MD) Simulations: Extensive MD simulations were performed on the individual aptamers and the four protein-DNA complexes to analyze their dynamic behavior, stability, and interaction patterns over time (up to 400 ns for aptamers and 200 ns for complexes).
- Binding Free Energy Calculations (MM-PBSA): The Molecular Mechanics-Poisson-Boltzmann Surface Area (MM-PBSA) method was used to quantify the binding free energies between DEK and the aptamers, providing insights into binding affinity.
- Per-Residue Free Energy Decomposition: This analysis identified specific amino acid residues in DEK that contribute most significantly to the binding energy with the aptamers.
- Hydrogen Bond Analysis: Hydrogen bond networks were analyzed to understand the specific and non-specific interactions stabilizing the protein-aptamer complexes.
- Mutational Study: Based on the interaction analysis, specific bases in the aptamers were identified as potential mutation sites to further enhance affinity and stability. They then simulated these mutations and evaluated their impact.
Datasets
The study utilized existing structural data from the Protein Data Bank (PDB) for the DEK protein domains. The primary sequence of the DTA aptamer was also used as the starting point for structural prediction. No new experimental datasets were generated or used for training in this computational study.
Key Insights and Ideas
- Methoxy Modification Enhances Stability: The 2'-OCH<sub>3</sub> modification of DTA significantly improves its structural stability, as evidenced by lower RMSD and RMSF values in MD simulations, without drastically reducing binding affinity. This is a critical finding for developing more robust aptamer therapeutics.
- Electrostatic Interactions Dominate Binding: The primary driving force for DEK-DTA binding is electrostatic interaction, particularly between positively charged residues (Lys, Arg) on DEK and the negatively charged phosphate backbone of the aptamer. This highlights the importance of charge complementarity.
- N-terminal Domain is a Stronger Binder: The DEK N-terminal domain exhibits a stronger binding affinity to both DTA and DTA_OMe compared to the C-terminal domain, as indicated by more negative binding free energies.
- Specific Bases are Key for Affinity: The study identified specific nucleotides within the aptamer that are crucial for interaction with DEK, particularly those involved in hydrogen bonding. This provides a rational basis for targeted aptamer design.
- Targeted Mutation for Optimal Design: Replacing the 29th base (cytosine) in DTA_OMe with thymine (resulting in DCO29DTO) yielded the most promising mutant, showing significantly enhanced stability and affinity. This demonstrates the power of structure-based design for aptamer optimization.
Key Results
- The 2'-OCH<sub>3</sub> modification of DTA (DTA_OMe) resulted in a smoother RMSD curve and lower RMSF values, indicating increased stability compared to the original DTA.
- Binding free energy calculations showed that while DTA_OMe had slightly lower binding energies than DTA for both DEK_N and DEK_C, the difference was minimal, suggesting that stability gains did not come at a significant cost to affinity. For example, DEK_N/DTA had a binding free energy of -97.72 kcal/mol, while DEK_N/DTA_OMe was -91.02 kcal/mol.
- Per-residue free energy decomposition identified key positively charged residues in DEK (e.g., Lys, Arg) that are critical for binding.
- Hydrogen bond analysis revealed a higher number of non-specific hydrogen bonds in N-terminal complexes, primarily involving the phosphate backbone, contributing to stability.
- In the mutational study, the DCO29DTO mutant exhibited the lowest binding free energy (-187.26 kcal/mol) and the smallest negative ΔΔG (-43.17 kcal/mol), indicating superior affinity and stability.
Limitations and Future Work
- Computational Approximation: While MM-PBSA is a widely used method, it's an approximation and doesn't fully capture all entropic contributions to binding free energy, which the authors acknowledge by stating they ignored entropy calculations for mutants due to computational cost.
- Limited Experimental Validation: The study is purely computational. Experimental validation of the designed aptamers and their therapeutic efficacy is the logical next step.
- Focus on Single Mutations: The mutational study primarily focused on single-site mutations. The authors suggest that exploring double-site or multi-site mutations could provide more valuable insights and potentially lead to even better aptamer designs.
- Force Field Generalizability: The authors note that the extended 2'-OCH<sub>3</sub>-DNA force field parameters developed in this study can be applied universally by other researchers, which is a valuable contribution for future computational studies of modified aptamers.
Summary updated